The Appetite Crusher Stack
Also Known As: CagriSema, CagriSema combination, Cagrilintide semaglutide, AM833 NN9535, Amylin GLP-1 dual agonist, Dual obesity drug, CagriSema stack, Amylin analog + GLP-1 agonist, Anti-obesity dual therapy, CagriSema combo, Cagrilintide with semaglutide, cagrilintide + semaglutide
The Appetite Crusher Stack is a research-grade Fixed-ratio combination: long-acting amylin analog targeting Amylin/calcitonin receptors studied in Weight Loss & Metabolism research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Investigational - In active human clinical trials; not yet approved.
An investigational amylin-plus-GLP-1 combination with strong trial weight loss.
At A Glance
| Category | Weight Loss & Metabolism |
|---|---|
| Compound Class | Fixed-ratio combination: long-acting amylin analog (cagrilintide) + GLP-1 receptor agonist (semaglutide) |
| Molecular Target | Amylin/calcitonin receptors (cagrilintide) + GLP-1 receptor (semaglutide); dual satiety and glucose regulation |
| Molecular Weight | combination |
| Amino Acid Sequence | cagrilintide + semaglutide |
| CAS Number | n/a |
| Half-Life | ~1 week (both components weekly SC) |
| WADA Status | not_listed |
| Evidence Tier | Investigational |
Mechanism Of Action
It hits the brain from two different angles. It activates the GLP-1 switch (which controls blood sugar and cravings) and the Amylin switch (which controls physical fullness in the stomach).
Studied For
- Obesity / overweight
- Type 2 diabetes
- Dual-mechanism weight loss
- GLP-1 plus amylin dual therapy
- Cardiometabolic disease
- HbA1c reduction
- Appetite suppression dual pathway
- Body weight reduction
- Metabolic syndrome
- Insulin resistance
- Blood sugar control
- Caloric intake reduction research
- Combination incretin amylin therapy
- Cardiovascular risk reduction
- obesity
- appetite suppression
- extreme weight loss
- metabolic control
Reported Research Findings
Phase 3 REDEFINE 1 (2025, 68 weeks) reported about 22.7 percent mean body-weight reduction in obesity, exceeding either component alone.
Safety And Handling Notes
Predominantly gastrointestinal, consistent with both component classes.
Investigational with no approved indication. Inherits the GLP-1 class thyroid C-cell and pancreatitis considerations. Research use only.
Regulatory Status
Investigational (Novo Nordisk); NDA filed with FDA 18 Dec 2025 on the REDEFINE 1 and REDEFINE 2 pivotal trials and under FDA review through 2026; company guidance points to a decision in Q4 2026, and no PDUFA date has been publicly confirmed. Would be the first once-weekly GLP-1 plus amylin analogue combination for weight management if approved. Note that the Phase 3 REDEFINE 4 head-to-head trial did not meet its primary endpoint of non-inferiority on weight loss versus tirzepatide at 84 weeks. Not approved.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.